Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice

There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibrotic peptide, and Ang converting enzyme 2 (ACE2) of the alternate RAS breaks down Ang II to antifibrotic peptide Ang‐(1‐7). In the present study, we investigated long‐term effects of ACE2 delivered by an adeno‐associated viral vector and short‐term effects of Ang‐(1‐7) peptide in multiple drug‐resistant gene 2‐knockout (Mdr2‐KO) mice. These mice develop progressive biliary fibrosis with pathologic features closely resembling those observed in PSC. A single intraperitoneal injection of ACE2 therapy markedly reduced liver injury (P < 0.05) and biliary fibrosis (P < 0.01) at both established (3‐6 months of age) and advanced (7‐9 months of age) disease compared to control vector‐injected Mdr2‐KO mice. This was accompanied by increased hepatic Ang‐(1‐7) levels (P < 0.05) with concomitant reduction in hepatic Ang II levels (P < 0.05) compared to controls. Moreover, Ang‐(1‐7) peptide infusion improved liver injury (P < 0.05) and biliary fibrosis (P < 0.0001) compared to saline‐infused disease controls. The therapeutic effects of both ACE2 therapy and Ang‐(1‐7) infusion were associated with significant (P < 0.01) reduction in hepatic stellate cell (HSC) activation and collagen expression. While ACE2 therapy prevented the loss of epithelial characteristics of hepatocytes and/or cholangiocytes in vivo, Ang‐(1‐7) prevented transdifferentiation of human cholangiocytes (H69 cells) into the collagen‐secreting myofibroblastic phenotype in vitro. We showed that an increased ratio of hepatic Ang‐(1‐7) to Ang II levels by ACE2 therapy results in the inhibition of HSC activation and biliary fibrosis. Conclusion: ACE2 therapy has the potential to treat patients with biliary diseases, such as PSC.

[1]  P. Angus,et al.  The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice , 2018, Scientific Reports.

[2]  P. Angus,et al.  The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders. , 2017, Current gene therapy.

[3]  R. Zhu,et al.  Epithelial-mesenchymal transition in liver fibrosis (Review) , 2016 .

[4]  N. LaRusso,et al.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis , 2016, Hepatology.

[5]  P. Angus,et al.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[7]  M. Manns,et al.  Characterization of animal models for primary sclerosing cholangitis (PSC). , 2014, Journal of hepatology.

[8]  M. Karin,et al.  Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis , 2014, Proceedings of the National Academy of Sciences.

[9]  Yun Feng,et al.  Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. , 2013, Oncology reports.

[10]  P. Angus,et al.  Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. , 2012, Clinical science.

[11]  R. Wells,et al.  The role of stem cells in liver repair and fibrosis. , 2011, The international journal of biochemistry & cell biology.

[12]  C. Ferrario.  ACE2: more of Ang-(1–7) or less Ang II? , 2011, Current opinion in nephrology and hypertension.

[13]  C. Liu,et al.  Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats , 2010, Laboratory Investigation.

[14]  J. Bosch,et al.  Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. , 2010, Journal of hepatology.

[15]  J. Dranoff,et al.  Portal fibroblasts: Underappreciated mediators of biliary fibrosis , 2010, Hepatology.

[16]  P. Angus,et al.  Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. , 2009, Clinical science.

[17]  P. Angus,et al.  Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[18]  D. Schuppan,et al.  Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. , 2008, The Journal of clinical investigation.

[19]  D. Schuppan,et al.  Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. , 2008, Gastroenterology.

[20]  Eytan Domany,et al.  Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice , 2007, Molecular Cancer Research.

[21]  M. Teixeira,et al.  The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). , 2007, Journal of hepatology.

[22]  Youhua Liu,et al.  Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. , 2006, The American journal of pathology.

[23]  Eytan Domany,et al.  Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. , 2006, Cancer research.

[24]  C. Ferrario,et al.  Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function , 2005, American journal of physiology. Heart and circulatory physiology.

[25]  Christopher J. Parsons,et al.  Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats , 2005, Hepatology.

[26]  H. Tilg,et al.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.

[27]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[28]  P. Angus,et al.  Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. , 2002, Gastroenterology.

[29]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[30]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[31]  R. Bataller,et al.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.

[32]  H. Herbst,et al.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.

[33]  A. Groen,et al.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.

[34]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[35]  P. Angus,et al.  Role of the Alternate RAS in Liver Disease and the GI Tract , 2015 .

[36]  S. Friedman.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. , 2008, Physiological reviews.